$HRGN
Harvard Apparatus Regenerative Technology Inc

2018 Q3 Form 10-Q Financial Statement

#000114420418044672 Filed on August 14, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2018 Q2 2017 Q2
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue $0.00
YoY Change -100.0%
Gross Profit $0.00
YoY Change -100.0%
Gross Profit Margin
Selling, General & Admin $940.0K $1.105M $1.039M
YoY Change 5.86% 6.35% -15.53%
% of Gross Profit
Research & Development $1.288M $928.0K $2.688M
YoY Change -45.52% -65.48% 60.0%
% of Gross Profit
Depreciation & Amortization $64.00K $70.00K $120.0K
YoY Change -28.89% -41.67% 9.09%
% of Gross Profit
Operating Expenses $2.228M $2.033M $3.727M
YoY Change -31.49% -45.45% 28.25%
Operating Profit -$2.228M -$2.033M -$3.727M
YoY Change -31.49% -45.45% 27.55%
Interest Expense $49.00K -$100.0K $120.0K
YoY Change 390.0% -183.33% -42.86%
% of Operating Profit
Other Income/Expense, Net $139.0K -$27.00K $124.0K
YoY Change 1444.44% -121.77%
Pretax Income -$2.089M -$2.060M -$3.600M
YoY Change -35.58% -42.78% 32.74%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$2.089M -$2.060M -$3.603M
YoY Change -35.58% -42.83% 32.85%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$368.7K -$553.8K -$1.935M
COMMON SHARES
Basic Shares Outstanding 5.663M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q3 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.543M $5.810M $3.420M
YoY Change 170.46% 69.88% -57.78%
Cash & Equivalents $3.543M $5.806M $3.424M
Short-Term Investments
Other Short-Term Assets $44.00K $36.00K $280.0K
YoY Change -83.94% -87.14% 75.0%
Inventory
Prepaid Expenses $229.0K $228.0K
Receivables $90.00K $130.0K $0.00
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $3.906M $6.197M $3.700M
YoY Change 132.78% 67.49% -55.64%
LONG-TERM ASSETS
Property, Plant & Equipment $544.0K $573.0K $960.0K
YoY Change -38.18% -40.31% -11.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $544.0K $573.0K $960.0K
YoY Change -37.61% -40.31% -11.11%
TOTAL ASSETS
Total Short-Term Assets $3.906M $6.197M $3.700M
Total Long-Term Assets $544.0K $573.0K $960.0K
Total Assets $4.450M $6.770M $4.660M
YoY Change 74.51% 45.28% -50.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $204.0K $167.0K $690.0K
YoY Change -83.14% -75.8% 15.0%
Accrued Expenses $547.0K $960.0K $1.160M
YoY Change 3.21% -17.24% 182.93%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $938.0K $1.363M $3.380M
YoY Change -54.82% -59.67% 74.23%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $938.0K $1.363M $3.380M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $938.0K $1.363M $3.380M
YoY Change -54.82% -59.67% 74.23%
SHAREHOLDERS EQUITY
Retained Earnings -$53.93M -$51.84M
YoY Change 14.73%
Common Stock $57.00K $57.00K
YoY Change -85.68%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.512M $5.407M $1.280M
YoY Change
Total Liabilities & Shareholders Equity $4.450M $6.770M $4.660M
YoY Change 74.3% 45.28% -50.53%

Cashflow Statement

Concept 2018 Q3 2018 Q2 2017 Q2
OPERATING ACTIVITIES
Net Income -$2.089M -$2.060M -$3.603M
YoY Change -35.58% -42.83% 32.85%
Depreciation, Depletion And Amortization $64.00K $70.00K $120.0K
YoY Change -28.89% -41.67% 9.09%
Cash From Operating Activities -$2.224M -$1.170M -$3.130M
YoY Change -29.84% -62.62% 108.67%
INVESTING ACTIVITIES
Capital Expenditures -$37.00K -$90.00K -$20.00K
YoY Change 270.0% 350.0% -77.78%
Acquisitions
YoY Change
Other Investing Activities $4.000K $10.00K
YoY Change
Cash From Investing Activities -$33.00K -$80.00K -$20.00K
YoY Change 230.0% 300.0% -77.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.000K 4.220M 0.000
YoY Change -99.81% -100.0%
NET CHANGE
Cash From Operating Activities -2.224M -1.170M -3.130M
Cash From Investing Activities -33.00K -80.00K -20.00K
Cash From Financing Activities 2.000K 4.220M 0.000
Net Change In Cash -2.255M 2.970M -3.150M
YoY Change 6.87% -194.29% -196.63%
FREE CASH FLOW
Cash From Operating Activities -$2.224M -$1.170M -$3.130M
Capital Expenditures -$37.00K -$90.00K -$20.00K
Free Cash Flow -$2.187M -$1.080M -$3.110M
YoY Change -30.79% -65.27% 120.57%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q4 us-gaap Restructuring And Related Cost Expected Number Of Positions Eliminated
RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
20 pure
us-gaap Revenues
Revenues
0 USD
CY2018Q2 us-gaap Revenues
Revenues
0 USD
CY2017Q2 us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
0 USD
us-gaap Net Income Loss
NetIncomeLoss
-3605000 USD
us-gaap Net Income Loss
NetIncomeLoss
-7444000 USD
CY2017Q4 us-gaap Restructuring Costs
RestructuringCosts
99000 USD
CY2017Q4 us-gaap Restructuring And Related Cost Description
RestructuringAndRelatedCostDescription
In addition, officers of the Company agreed to a temporary reduction in their salaries by 50% effective November 2017.
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1480000 USD
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
928000 USD
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2688000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4757000 USD
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2033000 USD
CY2018Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1105000 USD
CY2017Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1039000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2018000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
267000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
397000 USD
CY2018Q1 bstg Percentage Of Salary Of Officers On Contracted Rate
PercentageOfSalaryOfOfficersOnContractedRate
0.8 pure
CY2018Q2 us-gaap Cash
Cash
5806000 USD
CY2017Q4 us-gaap Cash
Cash
4038000 USD
CY2018Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
228000 USD
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
289000 USD
CY2018Q1 us-gaap Payments For Postemployment Benefits
PaymentsForPostemploymentBenefits
99000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
267000 USD
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
192000 USD
CY2017Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
206000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
397000 USD
us-gaap Depreciation
Depreciation
128000 USD
us-gaap Depreciation
Depreciation
236000 USD
us-gaap Operating Expenses
OperatingExpenses
3513000 USD
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
2033000 USD
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
3727000 USD
us-gaap Operating Expenses
OperatingExpenses
6775000 USD
dei Document Period End Date
DocumentPeriodEndDate
2018-06-30
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
3423000 USD
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
us-gaap Operating Income Loss
OperatingIncomeLoss
-3513000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-113000 USD
dei Entity Central Index Key
EntityCentralIndexKey
0001563665
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5271000 USD
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
127000 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
632000 USD
CY2018Q1 bstg Maximum Research And Development Expenses Reimbursement
MaximumResearchAndDevelopmentExpensesReimbursement
225000 USD
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5663419 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2507304 shares
CY2018Q2 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
300000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
220000 USD
CY2018Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
96000 USD
CY2017Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-124000 USD
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2018Q2 us-gaap Assets Current
AssetsCurrent
6197000 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
4413000 USD
CY2018Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
573000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
669000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-61000 USD
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2033000 USD
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3727000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-6775000 USD
bstg Fair Value Adjustment Of Warrants Gross
FairValueAdjustmentOfWarrantsGross
220000 USD
bstg Fair Value Adjustment Of Warrants Gross
FairValueAdjustmentOfWarrantsGross
669000 USD
CY2018Q2 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
127000 USD
CY2017Q4 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
0 USD
CY2018Q2 us-gaap Other Assets Current
OtherAssetsCurrent
36000 USD
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
86000 USD
CY2018Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
236000 USD
CY2017Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
16000 USD
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
8.00
CY2017Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
8.00
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5574734 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1411806 shares
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-8000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
267000 USD
dei Entity Registrant Name
EntityRegistrantName
Biostage, Inc.
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-42000 USD
bstg Grant Income
GrantIncome
135000 USD
CY2018Q2 bstg Grant Income
GrantIncome
76000 USD
CY2017Q2 bstg Grant Income
GrantIncome
0 USD
bstg Grant Income
GrantIncome
USD
us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
0 USD
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5663419 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2507304 shares
us-gaap Research And Development Arrangement Contract To Perform For Others Description And Terms
ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms
The SBIR grant has the potential to provide a total award up to $1.7 million. If Phase I is successful, and funding is available, a Phase II award of up to approximately $1.5 million would support pre-clinical testing of pediatric Cellspan™ Esophageal Implants planned to begin later in 2018. The Phase II Funds, if awarded, would be spent over an estimated two years.
CY2018Q2 us-gaap Assets
Assets
6770000 USD
CY2017Q4 us-gaap Assets
Assets
5045000 USD
bstg Product Distribution Agreement Term
ProductDistributionAgreementTerm
P10Y
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-1000 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-115000 USD
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
51000 USD
dei Trading Symbol
TradingSymbol
BSTG
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-759000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-275000 USD
CY2018Q2 us-gaap Liabilities
Liabilities
1363000 USD
CY2017Q4 us-gaap Liabilities
Liabilities
1622000 USD
bstg Stock Issued During The Period Conversion Of Preferred Stock
StockIssuedDuringThePeriodConversionOfPreferredStock
0 USD
CY2018Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
167000 USD
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
923000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
577000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-46000 USD
CY2018Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5663419 shares
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-2060000 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-3603000 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.11
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.55
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.94
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.63
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3229000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6193000 USD
CY2017Q4 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
4100000 USD
CY2018Q2 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
3600000 USD
CY2018Q2 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
900000 USD
CY2018Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
960000 USD
CY2017Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
383000 USD
CY2018Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
0 USD
CY2017Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
300000 USD
CY2017Q4 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2100000 USD
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3238000 shares
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3720000 shares
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1856000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1607000 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
89000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
125000 USD
CY2018Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
236000 USD
CY2017Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
16000 USD
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1363000 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1622000 USD
CY2018Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
250000 shares
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
64000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-25000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-125000 USD
CY2018Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1000000 USD
CY2018Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3400000 USD
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
0 USD
CY2018Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
800000 USD
CY2018Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
300000 USD
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0 USD
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
5322000 USD
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
6801000 USD
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
57000 USD
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
25000 USD
CY2018Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
57189000 USD
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
50157000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5022000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6801000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1768000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
483000 USD
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-51839000 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-48234000 USD
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
5407000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4038000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2941000 USD
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5806000 USD
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3424000 USD
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6770000 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5045000 USD
bstg Fair Value Of Warrant Liability Reclassified To Additional Paid In Capital
FairValueOfWarrantLiabilityReclassifiedToAdditionalPaidInCapital
0 USD
bstg Fair Value Of Warrant Liability Reclassified To Additional Paid In Capital
FairValueOfWarrantLiabilityReclassifiedToAdditionalPaidInCapital
3150000 USD
bstg Fair Value Of Liability Warrants Issued In Connection With Issuance Of Common Stock
FairValueOfLiabilityWarrantsIssuedInConnectionWithIssuanceOfCommonStock
0 USD
bstg Fair Value Of Liability Warrants Issued In Connection With Issuance Of Common Stock
FairValueOfLiabilityWarrantsIssuedInConnectionWithIssuanceOfCommonStock
3787000 USD
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
7000 USD
CY2018Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
7000 USD
CY2017Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
0 USD
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
0 USD
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
3000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.906 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.88 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2018Q2 us-gaap Share Price
SharePrice
4.52
CY2017Q4 us-gaap Share Price
SharePrice
0.87
CY2018Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
92212 shares
CY2017Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
92212 shares
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
1475000 USD
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0 USD
CY2018Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
51000 USD
CY2018Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
3.60
CY2018Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
3.60
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0265 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0278 pure
us-gaap Officers Compensation
OfficersCompensation
104000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-92000 USD
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-27000 USD
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
124000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-669000 USD
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
2098000 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1600000 shares

Files In Submission

Name View Source Status
0001144204-18-044672-index-headers.html Edgar Link pending
0001144204-18-044672-index.html Edgar Link pending
0001144204-18-044672.txt Edgar Link pending
0001144204-18-044672-xbrl.zip Edgar Link pending
bstg-20180630.xml Edgar Link completed
bstg-20180630.xsd Edgar Link pending
bstg-20180630_cal.xml Edgar Link unprocessable
bstg-20180630_def.xml Edgar Link unprocessable
bstg-20180630_lab.xml Edgar Link unprocessable
bstg-20180630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv500135_10q.htm Edgar Link pending
tv500135_ex31-1.htm Edgar Link pending
tv500135_ex31-2.htm Edgar Link pending
tv500135_ex32-1.htm Edgar Link pending
tv500135_ex32-2.htm Edgar Link pending